CTL Secures $10 Million in Funding to Revolutionize Immune Monitoring Technology

Cellular Technology Limited (CTL), a trailblazer in immune monitoring technology, has successfully raised $10 million in funding to accelerate its mission of making ELISPOT an exact science. For nearly two decades, CTL has provided comprehensive solutions and unparalleled expertise in immune monitoring, serving over 2,000 clients from both academia and the pharmaceutical industry worldwide. This new investment will enable CTL to enhance its CLIA-certified, GLP-compliant laboratory capabilities, which currently processes up to 450 samples per week across a wide range of assays, including ELISPOT, ELISA, and FACS. The funding will also support the expansion of its extensive Cryopreserved PBMC Library, ensuring that researchers have access to the largest commercially available donor library, which is crucial for robust assay performance and immune response studies. Furthermore, the investment will bolster the development of innovative products like the ImmunoSpot® Analyzers and BioSpot® Analyzers, which offer automated and objective data analysis for sophisticated immune monitoring applications. As CTL continues to innovate and expand its offerings, this funding not only signifies a vote of confidence in the company’s future but also its commitment to elevating the standards of immune monitoring to unprecedented heights. By enhancing its capabilities and product development efforts, CTL aims to facilitate groundbreaking research and foster collaborations that drive advancements in immunology and vaccine development, ultimately contributing to better health outcomes globally.